Poster Session: Unmoderated Posters
Thursday June 27, 2019 from
TBD
Lectures
  • UP-1 Predicting risk of disease progression during active surveillance for prostate cancer: analysis comparison of patient clinical features with a machine learning algorithm to the CANARY risk calculator
    Dr. M. Eric Hyndman, Canada
  • UP-2 An examination of the role of socioeconomic status in the relationship between depression and prostate cancer survivorship
    Dr. Gabriela Ilie, Canada
  • UP-3 PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center
    Dr. Michael Uy, Canada
  • UP-4 Self-reported health literacy as a modifier for prostate cancer screening
    Mr. Chase W Mallory, United States
  • UP-5 Identifying prostate cancer in men with non-suspicious multi-parametric magnetic resonance imaging of the prostate.
    Dr. Paul N Doan, Australia
  • UP-6 Clinical Outcomes and Detection Rates of Transperineal MRI/US Fusion Targeted Prostate Biopsy
    Dr. Nathan C. Wong, United States
  • UP-7 A Canadian Consensus Forum on the Management of Patients with Prostate Cancer
    Dr. Fred Saad, Canada
  • UP-8 Comparison of the cardiotoxicity of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data
    Mr. Jason Hu, Canada
  • UP-9 A machine learning approach to predicting progression on active surveillance for prostate cancer
    Dr. Madhur Nayan, United States
  • UP-10 Nerve size as marker of neurovascular bundle excision during radical prostatectomy
    Dr. Venetia VH Hoe, Australia
  • UP-11 Diagnostic Assessment Program for Prostate Cancer: Lessons Learned After 2 Years And Degree Of Compliance To Canadian Guidelines
    Dr. Waleed Shabana, Canada
  • UP-12 Patient acceptance of a preliminary asynchronous care model for prostate cancer survivors: A pilot study
    Mr. Jason Hearn, Canada
  • UP-14 Surgical decision-making rules and pattern recognition for error avoidance: task analysis of a robotic prostatectomy
    Dr. Avril J. Lusty, Canada
  • UP-15 Identifying clinician-related barriers to active surveillance for prostate cancer – a qualitative study
    Dr. Trent A Pattenden, Australia
  • UP-16 Comparison of LHRH agonist and antagonist agents efficacy to suppress testosterone levels in prostate cancer patients using mass spectrometry
    Mr. Jérémie Beck, Canada
  • UP-17 National consensus quality indicators to assess quality of care for active surveillance in low risk prostate cancer: a modified Delphi survey of Canadian Urologists/Radiation Oncologists
    Mr. Narhari Timilshina, Canada
  • UP-18 Patterns of mortality after prostate cancer: a SEER-based analysis
    Dr. Roderick Clark, Canada
  • UP-19 Qualitative and Quantitative Evaluation of a Prostate Cancer-Patient Empowerment Program
    Dr. Gabriela Ilie, Canada
  • UP-20 The oncological and pathological outcomes of prostate cancer patients undergoing delayed robotic-assisted radical prostatectomy after initial management by active surveillance
    Dr. Ali AA ABDULLAH, Canada
  • UP-21 A direct comparison of prostate cancer prediction models in a population undergoing multiparametric magnetic resonance imaging and only transperineal prostate biopsy
    Dr. Paul N Doan, Australia
  • UP-22 Characteristics and outcomes of real-world patients with metastatic castrate-resistant prostate cancer (mCRPC) in Alberta, Canada.
    Dr. Lawrence Mbuagbaw, Canada
  • UP-23 Management of castrate resistant prostate cancer: real world evidence in a regional cancer centre
    Ms. Emily C Evans, Canada
  • UP-25 Focal low dose-rate brachytherapy for low to intermediate prostate cancer: preliminary experience at an Australian institution.
    Dr. Elliot P Anderson, Australia
  • UP-26 An analysis of incidental prostate cancer diagnosed at radical cystoprostatectomy; does neo-adjuvant chemotherapy have an impact?
    Dr. Louise McLoughlin, Canada
  • UP-27 Uptake of reTUR in T1 bladder cancer in Ontario: an interrupted time series analysis involving 15 years of observation
    Dr. Marian S. Wettstein, Canada
  • UP-28 Adherence to guidelines in the management of high-risk non-muscle-invasive bladder cancer - Are patients receiving intravesical Bacillus Calmette-Guérin therapy appropriately?
    Miss Betty H Wang, Canada
  • UP-29 Safety and efficacy of transurethral resection of bladder tumour comparing spinal anaesthesia to spinal anaesthesia with an obturator nerve block: a systematic review and meta-analysis
    Mr. Anil Krishan, United Kingdom
  • UP-30 Impaired emotional, physical and social well-being in radical cystectomy patients
    Dr. Conrad C Maciejewski, Canada
  • UP-31 Sex differences amongst those with bladder cancer post cystectomy: a retrospective population-based study
    Mr. Iain TK MacIntyre, Canada
  • UP-32 Molecular subtyping to stratify the treatment of muscle-invasive bladder cancer: a cost effectiveness analysis
    Dr. Diana E. Magee, Canada
  • UP-33 The University of Alberta Experience with Radical Cystectomy via Minimally Invasive Approaches
    Dr. Alexander R Hengel, Canada
  • UP-34 Evaluation of financial toxicity in Canadian patients undergoing radical cystectomy
    Dr. Ryan McLarty, Canada
  • UP-35 Visual prediction of urothelial cell carcinoma grade and stage: a prospective clinical trial
    Dr. Heather Morris, Canada
  • UP-36 The prognostic value of urinary cytology after trimodal therapy for muscle-invasive bladder cancer
    Dr. Sophie O'Halloran, Canada
  • UP-37 Prehabilitation body mass index (BMI) target for complication risk reduction following radical cystectomy
    Dr. Louise McLoughlin, Canada
  • UP-38 Pathological Upstaging in Patients Undergoing Radical Cystectomy for clinically localized Denovo Muscle Invasive Bladder Cancer
    Dr. Ahmed Kotb, Canada
  • UP-39 Infantile Bacillus Calmette-Guerin Vaccination and Bladder Cancer Incidence: Preliminary Analysis
    Dr. Ahmed Kotb, Canada
  • UP-40 Clinical utility of serial creatinine measurements in patients undergoing radical cystectomy for urothelial cell carcinoma.
    Christopher Bitcon, Canada
  • UP-41 Bladder cancer guideline adherence in an Australian tertiary hospital
    Dr. Oliver v Best, Australia
  • UP-42 Opioids use after uro-oncologic surgeries in time of opioids crisis, the Quebec experience
    Bruno Turcotte, Canada
  • UP-43 Utilization of lymphadenectomy and predictors of lymph node yield in upper tract urothelial carcinoma
    Dr. Siv Venkat, United States
  • UP-44 Comparison of Radical Nephroureterectomy and Segmental Ureterectomy in Upper Tract Urothelial Carcinoma
    Dr. Siv Venkat, United States
  • UP-45 Disease recurrence patterns in high-risk nonmetastatic renal cell carcinoma patients post-nephrectomy with long-term follow-up
    Miss Shipra Taneja, Canada
  • UP-46 Treatment Outcomes with Percutaneous Thermal Ablation for Small Renal Masses
    Ms. Jennifer Wong, Canada
  • UP-47 A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes
    Dr. Paul N Doan, Australia
  • UP-48 Real world evidence of patient compliance to cabozantinib for metastatic renal cell carcinoma: a single Canadian center experience
    Mr. Jaehoon Kim, Canada
  • UP-49 Adrenal pheochromocytoma: tumor histology correlates with perioperative intensive care stay
    Dr. Jiefei Yao, Canada
  • UP-50 Time trends for drug specific adverse events in patients on sunitinib; implications for remote monitoring
    Mr. Jacob I. Wise, Canada
  • UP-51 Achieving Trifecta outcomes early in the robotic assisted partial nephrectomy learning curve
    Dr. Dhanika Samaranayake, Australia
  • UP-52 Outcomes and prognosticators following radical nephroureterectomy for upper tract urothelial carcinoma
    Ryan Satya Ramjiawan, Canada
  • UP-53 Cost-effectiveness analysis of post-orchiectomy management for clinical stage I non-seminoma germ cell testicular cancer
    Mr. David-Dan Nguyen, Canada
  • UP-54 Surgical outcomes in robotic-assisted partial nephrectomy for imperative versus elective indications – a propensity score-matched analysis.
    Dr. JO-LYNN S TAN, Australia
  • UP-55 Stimulated Raman Spectroscopy as a Method to Improve Access and Decrease Time Required to Determine Renal Biopsy Adequacy - A Pilot Study
    Dr. Miles Mannas, Canada
  • UP-56 Pooled Analysis of Bladder Function Post-Aquablation
    Dr. Dean S. Elterman, Canada
  • UP-57 Randomized Controlled Trial Comparing Holmium Laser Xpeeda Vaporesection and GreenLight XPS Vaporization of the Prostate: 6 months follow up
    Dr. Hazem M. Elmansy, Canada
  • UP-58 A Novel Method for GreenLight MoXy Laser Fiber Irrigation System to Improve Performance and Durability: A New Standard of Care?
    Mr. Kyle W. Law, Canada
  • UP-59 Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: Large, multi-center cohort
    Dr. Dean S. Elterman, Canada
  • UP-60 The Outcomes of Top-Down Holmium Laser Enucleation of the Prostate (HoLEP) versus Traditional HoLEP for the treatment of Benign Prostatic Hyperplasia (BPH): A randomized prospective comparative study
    Dr. Hazem M. Elmansy, Canada
  • UP-61 Routine Use of Focal Bladder Neck Cautery in 1116 consecutive Aquablation controls Postoperative Bleeding
    Dr. Dean S. Elterman, Canada
  • UP-62 Evaluating the acceptability of an electronic patient decision-aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Mr. David Bouhadana, Canada
  • UP-63 CARBON FOOTPRINT OF DISPOSABLE BPH MINIMALLY-INVASIVE SURGICAL DEVICES: A STANDARDIZED METHOD FOR TRANSURETHRAL PROSTATE SURGERY
    Dr. Kevin C. C. Zorn, Canada
  • UP-64 A Pilot Study to assess efficacy and safety of Methoxyflurane for pain control during Convective Thermal Therapy using Rezūm System in benign prostatic hyperplasia (BPH) – Final results
    Dr. Dean S. Elterman, Canada
  • UP-65 Rezūm water vapor therapy for catheter-dependent urinary retention: Real-world Canadian experience
    Dr. Dean S. Elterman, Canada
  • UP-66 Assessing the accuracy, quality, and readability of online educational health information related to the surgical management of benign prostatic hyperplasia
    Mr. David Bouhadana, Canada
  • UP-67 Incidental prostate cancer in transurethral resection of the prostate: a comparison of modern resection techniques
    Dr. Samuel S Jaquet, Canada
  • UP-68 Top-Down Thulium Fiber Laser (TFL) Enucleation of the Prostate: Early Postoperative Outcomes
    Dr. Hazem M. Elmansy, Canada
  • UP-69 Autopilot TURP: use of overnight surgical unit to enhance hospital flow and capacity
    James Hayes, Canada
  • UP-70 Etiology, urine metabolic risk factors, and urine oxalate patterns in patients with significant hyperoxaluria and recurrent nephrolithiasis
    Dr. Jonathan Moore, United States
  • UP-71 Miniaturized Ambulatory Percutaneous Nephrolithotomy (Mini-PCNL) versus Flexible Ureteroscopy(F-URS) in the Management of Lower Calyceal Renal Stones 10- 20mm: A propensity score matching analysis
    Dr. Hazem M. Elmansy, Canada
  • UP-72 Development of a New Canadian Endourology Group Stent Symptom Score (CEGSSS)
    Dr. Naeem Bhojani, Canada
  • UP-73 The impact of surgery and stone passage on kidney stone patient quality of life
    Dr. Brendan BR Raizenne, Canada
  • UP-74 Trends in the Surgical Management of Adult Urolithiasis in Ontario, Canada: A Population-Based Retrospective Cohort Study
    Dor Golomb, Canada
  • UP-75 Not every low-dose is low-dose: Impact of revising low-dose CT protocol on mean effective radiation exposure
    Miss Claudia Deyirmendjian, Canada
  • UP-76 Ureteroscopy with conscious sedation is safe and efficacious: a single-centre, prospective study
    Dr. Kunal Jain, Canada
  • UP-77 Over-the-counter alkali agents to raise urine pH and citrate excretion: a randomized crossover study in healthy adults
    Dr. Naeem Bhojani, Canada
  • UP-78 Making the grade: Can intraoperative fragmentation grading during shockwave lithotripsy predict treatment success?
    Dr. Callum Andrew Lavoie, Canada
  • UP-79 Antibiotic prophylaxis for prevention of infectious complications after shockwave lithotripsy, a systematic review and meta-analysis
    Dr. Borna Tadayon Najafabadi, Canada
  • UP-80 ASSESSING THE ASSESSMENT: INTER-USER VARIABILITY AND PROFICENCY OF URETERAL WALL THICKNESS MEASUREMENTS IN STONE PATIENTS
    Mr. Patrick S Albers, Canada
  • UP-81 Ureteral wall thickness as a novel predictor for failed retrograde stent placement
    Dr. Nick S Dean, Canada
  • UP-82 Are video gamers better Urologists? The impact of video games on surgical skill in flexible ureteroscopy
    Dr. Bruce Gao, Canada
  • UP-83 Are post-operative nephrostomy tubes needed in the mini percutaneous nephrolithotomy era?
    Dr. JO-LYNN S TAN, Australia
  • UP-84 Impact of travel distance on clinical outcomes in patients receiving treatment for urolithiasis
    Dr. Danielle A Jenkins, Canada
  • UP-85 Characterizing patients with multiple same-sided ureteric stones
    Mr. Matthew A Mancuso, Canada
  • UP-86 Impact of growing multi-specialty use of robotic surgery on delivery of robotic urologic surgery in Canada - a 10-year review of 2 academic centers
    Dr. Ahmed S. Zakaria Ahmed, Canada
  • UP-87 Global Greenlight group: Largest international Greenlight experience for benign prostatic hyperplasia with 5-year outcomes
    Mr. Kyle W. Law, Canada
  • UP-88 Three-Year Outcomes after Aquablation Compared to TURP: Longest Reported Followup with SustainedEfficacy and Ejaculatory Improvements
    Dr. Kevin C. C. Zorn, Canada
  • UP-89 Nephrostomy tube vs. ureteral stent for obstructing septic calculi: a nationwide propensity score matched analysis
    Rachel Wong, Canada
  • UP-90 Evaluation of trends in treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) across Canada during the COVID-19 pandemic
    carlos eduardo stecca, Canada
  • UP-91 Association between patients' and urologists' perspectives with telemedicine
    Bruno Turcotte, Canada
  • UP-92 The impact of COVID-19 lockdown on prostate cancer investigations - an Australian experience
    Dr. Sean Ong, Australia
  • UP-93 Prolonged follow up: the impact of telehealth implementation in a urology clinic during the Covid-19 pandemic.
    Dr. Trent A Pattenden, Australia
  • UP-94 The surgical management of prostate cancer during COVID-19 lockdown in Australia
    Dr. Sean Ong, Australia
  • UP-95 Virtual OSCE examinations during COVID-19: A 360 satisfaction assessment from examiners and candidates
    Dr. Danielle A Jenkins, Canada
  • UP-96 Lessons learned with remote research among older adults during COVID-19, a qualitative reflection
    Miss Rachel E Gutschon, Canada
  • UP-97 Using narrow band imaging during flexible cystoscopy to improve the detection of pathognomonic indicators of bladder pain syndrome: a pilot study
    Dr. Christopher Ciampa, Australia
  • UP-99 A Novel Sublingual Vaccine for Recurrent Urinary Tract Infection in Women: Preliminary Results from the Pre-Covid-19 Cohort in the first North American Uromune Early Clinical Experience Study
    Dr. J. Curtis Nickel, Canada
  • UP-100 Association between radical cystectomy prophylactic antimicrobial regimen and post-operative infection
    Dr. James Ross, Canada
  • UP-101 Vesicovaginal fistula prevalence, repair patterns, and failures: a retrospective population-based analysis
    Dr. Sarah R. Neu, Canada
  • UP-102 Y-V Plasty Reconstruction For The Treatment of Refractory Bladder Neck Contracture: Clinical and Patient-Reported Outcomes
    Dr. Samer Shamout, Canada
  • UP-103 Refractory Lower Urinary Tract Symptoms (LUTS) Following Successful Urethroplasty: Further Examining "LUTS Failure"
    Dr. David W. Chapman, Canada
  • UP-104 Post-Void Dribbling After Urethroplasty: Incidence and Associations
    Jordan Bekkema, Canada
  • UP-105 24 months Follow up of Dorsal Buccal Mucosal Graft Urethroplasty for Vesico-Urethral Anastomotic Stricture Post radical Prostatectomy
    Dr. Waleed Shabana, Canada
  • UP-106 Patient-perceived changes in penile appearance post-urethroplasty
    Dr. Dylan Hoare, Canada
  • UP-107 The incidence and associations of 90-day complications after urethroplasty
    Mr. Ryan Noble, Canada
  • UP-108 Morbidity and Predictor for Delayed Recognition of Iatrogenic Ureteric Injuries
    Dr. Jennifer A. Locke, Canada
  • UP-110 Characterizing clinical differences between idiopathic and traumatic stricture patients: analysis from a single institution
    Dr. Alexander E Kiciak, Canada
  • UP-111 The burden of urethral stricture disease in the province of Ontario
    Dr. R. Christopher Doiron, Canada
  • UP-112 Predictors of Perioperative and One-Year Renal Functional Outcomes in Laparoscopic Kidney Donors
    Dr. Ryan Sun, Canada
  • UP-113 Characterizing renal transplant recipients with urethral strictures
    Dr. Julie S Wong, Canada
  • UP-114 Does the skin to vessel distance for renal transplant recipients predict surgical outcomes?
    Dr. Braden Millan, Canada
  • UP-115 Urethral bulking agents for the treatment of stress urinary incontinence in women: a systematic review
    Dr. Venetia VH Hoe, Australia
  • UP-116 Age-Stratified Continence Outcomes of Robotic-Assisted Radical Prostatectomy
    Mr. Iman Sadri, Canada
  • UP-117 Long-term outcomes of polyacrylamide hydrogel (Bulkamid®) treatment in women with stress urinary incontinence
    Dr. Venetia VH Hoe, Australia
  • UP-118 Treating overactive bladder with transcutaneous tibial nerve stimulation: does increasing the volume of stimulation sessions improve patient outcomes?
    Dr. Christopher Ciampa, Australia
  • UP-119 Improving patient outcomes in overactive bladder (OAB) with transcutaneous tibial nerve stimulation (TTNS): a systematic review
    Dr. Christopher Ciampa, Australia
  • UP-120 Adjustable Trans-Obturator Male System (ATOMS) for Stress Urinary Incontinence: New Zealand Experience
    Dr. Mohit Bajaj, New Zealand
  • UP-121 Impact of radiotherapy for prostate cancer on bladder function as demonstrated on urodynamics study – a systematic review
    Dr. Venetia VH Hoe, Australia
  • UP-122 Urodynamics finding of detrusor overactivity underestimates the prevalence of overactive bladder in men following radical prostatectomy
    Dr. Henry Han-I Yao, Canada
  • UP-123 Retrospective study of the long-term efficacy of sacral nerve stimulation in underactive bladder patients: A single institution experience
    Miss Cristina Alina Evoescu, Canada
  • UP-124 Antagonism of the p75NTR receptor decreases MMP-9 activity and increases NGF in urothelial cells
    Aalya Hamouda, Canada
  • UP-125 A Cost-Effectiveness Analysis of Bladder Management Strategies in Neurogenic Lower Urinary Tract Dysfunction after Spinal Cord Injury: A Publicly Funded Health Care Perspective
    Dr. Samer Shamout, Canada
  • UP-126 Shared decision making for pediatric elective penile surgery
    Mr. Wyatt MacNevin, Canada
  • UP-127 Characterizing the safety, effectiveness, and patient population of laparoscopic pyeloplasty for ureteropelvic junction obstruction: A Canadian single-centre, single-surgeon experience
    Hark Randhawa, Canada
  • UP-128 An old friend revisited: the open pyeloplasty in children. Indications, outcomes and complications for a large prospectively collected single surgeon experience of 121 patients
    Dr. Yuding Wang, Canada
  • UP-129 Management of intrinsic versus extrinsic causes of ureteropelvic junction obstruction in children- outcomes and complications from a large prospective cohort study
    Jaskirat Saini, Canada
  • UP-130 Early complications of non-neonatal circumcisions performed by pediatric urologists: a secondary analysis of the pediatric National Surgical Quality Improvement Program database
    Ms. Nadeesha R. Samarasinghe, Canada
  • UP-131 International Hypospadias Practice Pattern Survey
    Ms. Melissa McGrath, Canada
  • UP-132 Early postoperative outcomes of ureteric reimplantation surgery for pediatric vesicoureteral reflux: results from the National Surgical Quality Improvement Program Pediatric database
    Mr. Youshan Ding, Canada
  • UP-133 Severe ureteropelvic junction obstruction (UPJO)-like hydronephrosis in asymptomatic infants: to operate or not?
    Dr. Abdulrahman Alsabban, Canada
  • UP-134 Evaluation of renal measurements of isolated high-grade congenital hydronephrosis (HGH) in both supine and prone positions.
    Dr. Amr Hodhod, Canada
  • UP-135 Development of a portable endoscopic training system for urology
    Dr. Jeremy Cepek, Canada
  • UP-136 Consistency of examiner scoring of an objective structured clinical examination (OSCE)
    Mr. Iain TK MacIntyre, Canada
  • UP-137 A synchronous motion-tracking and video-capture system for objective assessment and training in ureteroscopy
    Miss Jessica Trac, Canada
  • UP-138 Perceptions and attitudes of learners towards video recording of their operative performance for assessment of surgical skills
    Bruce Li, Canada
  • UP-139 Practical Telemedicine and Digital Health for Learners-A New Curriculum or a Necessity?
    Dr. O. Emmanuel Abara, Canada
  • UP-140 Predictors of Ureteroscopic Aptitude among Novice Trainees
    Dr. Ryan Sun, Canada
  • UP-141 Current educational interventions for improving crisis resource management skills in surgery
    Mr. Ishan Aditya, Canada
  • UP-142 Urology and Academic Productivity in Thunder Bay Regional Heath Science Center Surgical Specialities
    Dr. Waleed Shabana, Canada
  • UP-143 Finding the cause of the curve: development of an in vitro 3D Peyronie’s disease model
    Dr. Luke Witherspoon, Canada
  • UP-144 Predictors of success after bilateral vasoepididymostomy performed during vasectomy reversal
    Dr. Jesse Ory, United States
  • UP-145 Less mortality and less major adverse cardiovascular events (MACE) under Long-term testosterone therapy (TTh): 15-year data from a prospective controlled registry study
    Mr. Ahmad A. Al-Qudimat, Qatar
  • UP-147 Percutaneous epididymal sperm aspiration for men with obstructive azoospermia: predictors of outcomes
    Mr. Nawar Touma, Canada
  • UP-148 Age-stratified potency outcomes of bilateral nerve sparing robotic-assisted radical prostatectomy
    Mr. Adel Arezki, Canada
  • UP-149 Using Artificial Intelligence to predict semen upgrading after microsurgical varicocele repair
    Dr. Jesse Ory, United States
  • UP-150 Insurance approval rates for collagenase clostridium histolyticum prior to discontinuation: a Canada-wide analysis
    Dr. Benjamin Shiff, Canada
  • UP-151 Possible effects of Saffron (Crocus sativus) in treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled trial
    Dr. Borna Tadayon Najafabadi, Canada
  • UP-152 Intracavernous injection of Botulinum toxin improves erectile function in an animal model of bilateral cavernous nerve injury
    Dr. Jeffrey D. D. Campbell, Canada
  • UP-153 Canadian provider perspectives on Collagenase Clostridium histolyticum for the treatment of Peyronie’s disease and the impact of its discontinuation
    Dr. Uday Mann, Canada
  • UP-154 Getting a straight answer: survey of collagenase histolyticum treatment practises for treating Peyronie’s Disease
    Mr. Adam Levschuk, Canada
  • UP-155 A novel cell-sorting strategy for the isolation of germ cells transitioning into meiosis
    Ms. Meghan A Robinson, Canada
  • UP-156 A xeno-free defined culture method for the in vitro expansion of human spermatogonial stem cells
    Ms. Meghan A Robinson, Canada
  • UP-157 Vasectomy Reversal Following Percutaneous Epididymal Sperm Aspiration (PESA): Operative Implications and Post-Operative Outcomes.
    Dr. Udi Blankstein, Canada
  • UP-158 Development of a machine learning algorithm for Peyronie’s disease curvature assessment
    Dr. Luke Witherspoon, Canada
  • UP-160 Google searches are a poor-quality source of information for erectile dysfunction treatment.
    Dr. Trent A Pattenden, Australia
  • UP-161 Treatment of Peyronie’s disease patients with Collagenase clostridium histolyticum: Clinical Significance and Outcomes
    Dr. Raidh R Talib, Qatar
  • UP-162 The hard facts: Patient information and trends in the current use of restorative therapy for the treatment of erectile dysfunction.
    Ryan Satya Ramjiawan, Canada
  • UP-163 Deep learning-based automated sperm identification for non-obstructive azoospermia patients
    Mr. Ryan Lee, Canada
  • UP-164 Generation of peritubular myoid-like cells from human induced pluripotent stem cells
    Ms. Meghan A Robinson, Canada
  • UP-165 Impact of Physician Assistants on patient volume at an outpatient Canadian urology clinic
    Mr. James Misurka, Canada
  • UP-166 A prospective evaluation of health literacy in an outpatient prostate cancer ambulatory clinic
    Mr. Karnvir S Rai, Canada
  • UP-167 Conflict of interest disclosures in oral presentations at major urological conferences in 2020
    Miss Anique ALR Le Roux, Canada
  • UP-169 Research productivity and impact of Canadian academic urologists: national trends in academic metrics as it relates to gender, subspecialty, and faculty appointment
    Rebecca Joy Power, Canada
  • UP-170 Gender disparity in editorial boards of major urology journals
    Miss Anudari Zorigtbaatar, Canada
  • UP-171 Prospective multicentre outcome following surgical intervention for chronic scrotal content pain
    Mr. Andrew Nashed, Canada
  • UP-172 Cost analysis and feasibility of a minimally invasive, in-office hydrocelectomy
    Dr. Andrew A. Di Pierdomenico, Canada
  • UP-173 Are we prescribing medications responsibly to nonagenarians seeking urologic care?
    Miss Emily Chedrawe, Canada

© 2021 CUA 74th Annual Meeting